Biogen (BIIB) Total Liabilities (2009 - 2026)

Biogen has reported Total Liabilities for 18 years, with the latest figure at $13.2 billion in Q2 2026.

• On a quarterly basis, Total Liabilities rose 23.77% year-over-year to $13.2 billion in Q2 2026; TTM through Jun 2026 was $13.2 billion, a 23.77% increase from a year earlier, with the FY2025 full-year figure at $11.2 billion, down 1.33% from the prior year.
• Total Liabilities was $13.2 billion for Q2 2026 at Biogen, up from $10.8 billion in the prior quarter.
• The five-year high for Total Liabilities was $13.7 billion in Q3 2023, with the low at $10.7 billion in Q2 2025.
• Average Total Liabilities over 5 years is $11.6 billion, with a median of $11.3 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Total Liabilities declined 19.08% in 2023, then rose 23.77% in 2026.
• Over 5 years, Total Liabilities stood at $11.2 billion in 2022, then climbed by 7.88% to $12.0 billion in 2023, then retreated by 5.91% to $11.3 billion in 2024, then declined by 1.33% to $11.2 billion in 2025, then increased by 18.38% to $13.2 billion in 2026.
• The last three Total Liabilities figures came in at $13.2 billion (Q2 2026), $10.8 billion (Q1 2026), and $11.2 billion (Q4 2025), per Business Quant data.